Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aethlon Medical (AEMD)

Aethlon Medical (AEMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Financial Summary for [[ item.sessionDateDisplayLong ]]
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.

Fiscal Year End Date: 03/31

(Values in U.S. Thousands) Mar, 2025 Mar, 2024 Mar, 2023 Mar, 2022 Mar, 2021
Sales 0 0 570 290 660
Sales Growth unch -100.00% +96.55% -56.06% +1.54%
Net Income -13,390 -12,210 -12,030 -10,420 -7,890
Net Income Growth -9.66% -1.50% -15.45% -32.07% -23.47%
(Values in U.S. Thousands) Mar, 2025 Mar, 2024 Mar, 2023 Mar, 2022 Mar, 2021
Total Assets 7,360 8,250 17,510 19,420 10,670
Total Assets Growth -10.79% -52.88% -9.84% +82.01% +2.69%
Total Liabilities 2,240 2,480 2,440 2,430 1,380
Total Liabilities Growth -9.68% +1.64% +0.41% +76.09% +24.32%
(Values in U.S. Thousands) Mar, 2025 Mar, 2024 Mar, 2023 Mar, 2022 Mar, 2021
Operating Cash Flow -7,650 -10,130 -10,510 -9,770 -6,760
Operating Cash Flow Growth +24.48% +3.62% -7.57% -44.53% -30.00%
Net Cash Flow 70 -9,090 -2,530 7,250 300
Change in Net Cash Flow +100.77% -259.29% -134.90% +2,316.66% -94.81%
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar